Can’t hack it? Bellus tolls for GSK phase III cough drug
GSK plc reported phase III results for camlipixant, a P2X3 receptor antagonist, from the Calm-1 and Calm-2 trials. According to GSK, the Calm-1 trial met its primary endpoint, with 50 mg twice daily reducing 24-hour cough frequency versus placebo at week 12. GSK’s walk-away from the program also highlighted Trevi Therapeutics’ Haduvio, which had positive phase II data in June.
How this was made
The 30-second read
Why it matters
The article frames GSK’s Phase 3 outcome as opening opportunity for Trevi, and pairs that with a specific efficacy claim for camlipixant in Calm-1/Calm-2 and a same-day TRVI price jump.
Market read
Traders may treat the GSK Phase 3 setback plus Trevi’s Phase 2 positivity as a near-term catalyst for TRVI sentiment and positioning.
What to watch
Investors may be underweighting differences in mechanism, endpoints, and patient selection between camlipixant (P2X3 antagonist) and Haduvio (oral nalbuphine ER), which can drive divergent efficacy and safety outcomes.
Background
GSK reportedly walked away from camlipixant after “dicey” Phase 3 results, while Trevi’s Haduvio showed positive Phase 2 data in June.
Ticker impact
Trevi’s Haduvio oral nalbuphine ER is cited as having positive Phase 2 data in June, supporting a read-through to its cough pipeline.
Likely supports continued upside bias versus peers, but magnitude depends on how investors value Phase 2 versus the broader Phase 3 landscape.
The article links GSK’s Phase 3 walk-away to increased opportunity for Trevi, and provides a specific Phase 2 positivity timing (June) plus a same-day TRVI price move (up 9.9% on July 17).
Market effects
Refractory chronic cough pipeline sentiment may shift toward remaining P2/P3 assets after a Phase 3 setback at a large pharma.
US-listed biotech sentiment (NASDAQ) may strengthen as investors price in pipeline opportunity.
Large pharma Phase 3 discontinuations can re-rate global specialty pharma cough franchises and trial probability assumptions.
Counterpoint
A Phase 2 positive signal may not translate into Phase 3 success, so the read-through from GSK’s failure could be overstated.
Key entities
- companyTrevi Therapeutics
NASDAQ-listed Trevi, whose Haduvio oral nalbuphine ER is described as having positive Phase 2 data in June; TRVI shares rose 9.9% on July 17.
- companyGSK plc
London-based GSK, whose camlipixant Phase 3 results are described, including Calm-1/Calm-2 primary endpoint performance at week 12.
